2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

654. Multiple Myeloma: Pharmacologic Therapies: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transplantation, Bispecific Antibody Therapy, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Machine Learning, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Immunology, White Blood Cell Disorders, Infectious Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Translational Research, Clinical Research, Clinical Trials, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult, Animal Model
PAPER

2245 Trial in progress: Determination 2, a phase 3 trial evaluating risk-adapted and response-adapted treatment strategies in transplant-eligible patients (pts) with newly diagnosed multiple myeloma (NDMM)

Clifton C. Mo, MD, Susanna J. Jacobus, MBA, MSc2, Mounzer E. Agha, MD3, Zachary M. Avigan, MD, MHS4, Jesús G. Berdeja, MD5, Tondre Buck, MD6, Alexander A. Dew, DO, MS7, Edward A. Faber Jr, MD8, Hamza Hassan, MD9, James J Ignatz-Hoover, MD PhD10, Shivi Jain, MD11, Jonathan L Kaufman, MD12, Abdullah Khan, MBBS13, Mary Kwok, MD14, Eben I. Lichtman, MD15, John McKay, DO16, Eva Medvedova, MD17, Prerna Mewawalla, MD18, Natalia Neparidze, MD19, Robert Orlowski, MD, PhD20, Matthew J. Pianko, MD21, Emily B. Saul, DO22, Asya Varshavsky Yanovsky, MD, PhD23, Jeffrey A. Zonder, MD24, Yvonne Efebera, MD, MPH25, Andrew Kin, MD26, David E. Avigan, MD27, Noopur Raje, MD28, Andrew J. Yee, MD29, Adam S. Sperling, MD, PhD30, Mehmet Kemal Samur, PhD31, Ajantha Nithi32, Amy Thomas33, Diane Warren34, Lee-Jen Wei, PhD35, Kenneth Anderson, MD36, Jacob Laubach, MD37, Omar Nadeem, MD38, Shonali Midha, MD39, Poy Theprungsirikul, MD40, Tarek Mouhieddine, MD41, Yuxin Liu, MD42, Nikhil Munshi, MD43, Paul G. Richardson, MD44
1 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
2 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
3 University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
4 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States
5 Greco-Hainsworth Tennessee Oncology Centers for Research, Nashville, Tennessee, United States
6 Gibbs Cancer& Research Institute, Spartanburg Medical Center, Center for Hematology/Oncology, Spartanburg Regional Healthcare System, Spartanburg, South Carolina, United States
7 Duke Cancer Institute, Durham, North Carolina, United States
8 University of Cincinnati Medical Center, Cincinnati, Ohio, United States
9 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
10 University Hospitals Seidman Cancer Center, Cleveland, Ohio, United States
11 Rush University Medical Center, Chicago, Illinois, United States
12 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
13 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
14 Fred Hutchinson Cancer Center, University of Washington, Seattle, Washington, United States
15 UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
16 Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States
17 Oregon Health and Science University, Portland, Oregon, United States
18 Allegheny Health Network, Pittsburgh, Pennsylvania, United States
19 Yale University School of Medicine, Yale Cancer Center, New Haven, Connecticut, United States
20 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
21 University of Michigan, Ann Arbor, Michigan, United States
22 Columbus Oncology and Hematology Associates, Columbus, Ohio, United States
23 Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
24 Karmanos Cancer Institute / Wayne State University, Detroit, Michigan, United States
25 OhioHealth, Columbus, Ohio, United States
26 Karmanos Cancer Institute / Wayne State University, Detroit, Michigan, United States
27 Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States
28 Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, United States
29 Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, United States
30 Stanford University, Palo Alto, California, United States
31 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
32 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
33 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
34 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
35 Harvard T.H. Chan School of Public Health, Boston, Massachusetts, United States
36 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
37 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
38 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
39 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
40 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
41 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
42 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
43 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States
44 Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States

Background and Significance

The DETERMINATION trial of lenalidomide-bortezomib-dexamethasone (RVd) induction ± high-dose melphalan and autologous stem cell transplant (HDM-ASCT), followed by R maintenance until disease progression (PD), showed a progression-free survival (PFS) but no overall survival benefit with RVd+ASCT vs RVd alone in transplant-eligible NDMM pts, indicating the potential of deferred ASCT in select pts. Induction therapy now comprises quadruplets that offer high rates of measurable residual disease-negative (MRD-neg) responses; sustained (s)MRD-neg status is correlated with PFS and an accepted trial endpoint, enabling MRD-adapted, ASCT-sparing approaches. Novel therapies for relapsed MM including CAR T cells, bispecific antibodies, and the oral cereblon E3 ligase modulators (CELMoDs) are also showing promise in NDMM.

With these advances, some pts with NDMM may now achieve long-lasting remissions with quadruplet induction and long-term maintenance; however, others with high-risk disease and/or MRD-positive (pos) status may still relapse rapidly. These pts have differing needs; the former require improved tolerability and safety of induction/maintenance regimens plus further improvements in efficacy, while the latter need more effective drugs and consolidation strategies to deepen and sustain responses. Risk-/response-adapted studies evaluating next-generation novel agents and approaches to address these needs are warranted. We describe the randomized, multicenter, phase 3 DETERMINATION 2 trial (ClinicalTrials.gov NCT07624513) evaluating novel quadruplet induction followed by cytogenetic risk- and MRD-adapted consolidation and/or maintenance in NDMM.

Study Design and Methods

DETERMINATION 2 is planned to enroll 720 transplant-eligible pts aged 18–75 yrs with NDMM per IMWG criteria (≥10% clonal bone marrow plasma cells or biopsy-proven bony or extramedullary disease/plasmacytoma plus ≥1 CRAB feature/MM-defining event), established cytogenetic risk status (IMWG 2024), adequate hematologic, hepatic, and renal (creatinine clearance ≥30 mL/min) function, measurable disease, and ECOG performance status ≤2. Pts may have received prior treatment for smoldering MM (not anti-CD38 or anti-BCMA-based therapy). Pts will receive 8 x 4-week induction cycles of subcutaneous (SC) isatuximab 1400 mg (selected based on immunomodulatory and multiple anti-MM effects) via on-body injector on (d 1 and 15, plus d 8 and 22 in cycle 1), oral iberdomide 1 mg (selected based on substantial activity and potentially reduced risk of second primary malignancies) on d 1–21, SC bortezomib 1.3 mg/m2 on d 1, 8, 15, and 22, and intravenous/oral dexamethasone 20 mg on d 1, 2, 8, 9, 15, 16, 22, and 23. Post-induction (~602 pts evaluable for cohort assignment), pts with MRD-neg (10-5; NGS) ≥very good partial response (VGPR) and standard-risk cytogenetics (Cohort 1; ~234 pts) will receive 36 x 4-week cycles of isatuximab 1400 mg on d 1 plus iberdomide 1 mg on d 1–21, after which pts who remain MRD-neg will continue iberdomide to PD while MRD-pos/indeterminate pts will continue isatuximab-iberdomide to PD. Pts with <VGPR or who are MRD-pos/indeterminate post-induction and/or have high-risk cytogenetics (Cohort 2; ~368 pts) will be randomized (1:1) to receive HDM-ASCT or 8 x 4-week cycles of IV linvoseltamab (selected based on activity in pts with high-risk cytogenetics and favorable toxicity profile), followed by isatuximab-iberdomide to PD. The primary endpoint in Cohort 1 is sMRD-neg (IMWG 2024) complete response (CR) rate after 36 cycles of isatuximab-iberdomide; the study has 88% power to detect an increase in sustained MRD-neg CR from 60% (historical controls) to 70% (α=0.021). The Cohort 2 primary endpoint is MRD-neg CR rate at 1-yr post-randomization; assuming 184 pts are randomized per arm, the study has 83% power to detect a 15 percentage-point difference in the primary endpoint (α=0.025). Key secondary endpoints in both Cohorts are PFS, best response rates, health-related quality of life, and safety and tolerability. 

DETERMINATION 2 began recruiting in August 2026, with a target of 56 sites in the US. The trial will provide insights into the efficacy and safety of quadruplet induction with isatuximab-iberdomide-bortezomib-dexamethasone followed by isatuximab-iberdomide maintenance in standard-risk, MRD-neg pts or followed by HDM-ASCT or linvoseltamab consolidation plus isatuximab-iberdomide maintenance in high-risk and/or MRD-pos pts.

Clifton C. Mo, MD: Regeneron - Honoraria; Kryopharm - Honoraria; Johnson & Johnson - Honoraria; GSK - Honoraria; Sanofi - Research Funding; Regeneron - Research Funding; BMS - Research Funding; GSK - Consultancy (Includes expert testimony)